Afreximbank supplies early-stage money to de-risk project in preparation efforts and expedite project bankability and financial ending, stated to an updates release.
The project, based in South Africa’s Coega Special Economic Zone, entails the research, development, and manufacturing of high-demand routine veterinary vaccines including Bluetongue Virus, Brucellosis, Rift Valley Fever, Foot-and-Mouth Disease, Peste des Petits Ruminants, African Horse Sickness, and African Swine Fever using Dyadic International’s proprietary technology. Animal diseases pose direct threats to public health and food sovereignty in the Southern African Development Community region, reveals the investigation.
The project is expected to produce up to 27 million doses per year at peak capacity and will transform access to normal vaccines by improving current supply deficits by up to 16 percent, said to the release, and it also said that it will create over 9,000 a job during construction and operation.
Dr. Julian Naidoo, Chief Executive Officer of Rubic One Health, and Kanayo Awani, Executive Vice President, Intra African Trade Bank, Afreximbank, signed the agreement.